ICAD Stock Overview
Engages in the provision of cancer detection and therapy solutions in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
iCAD, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.83 |
| 52 Week High | US$2.65 |
| 52 Week Low | US$1.18 |
| Beta | 1.43 |
| 1 Month Change | 7.65% |
| 3 Month Change | 17.31% |
| 1 Year Change | 2.23% |
| 3 Year Change | -70.34% |
| 5 Year Change | -79.67% |
| Change since IPO | -97.89% |
Recent News & Updates
Recent updates
iCAD, Inc. (NASDAQ:ICAD) Looks Just Right With A 47% Price Jump
Nov 09
iCAD, Inc. (NASDAQ:ICAD) Stock Rockets 26% But Many Are Still Ignoring The Company
Aug 21iCAD, Inc.'s (NASDAQ:ICAD) P/S Still Appears To Be Reasonable
Jun 27iCAD, Inc. (NASDAQ:ICAD) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Feb 29We're Hopeful That iCAD (NASDAQ:ICAD) Will Use Its Cash Wisely
Sep 27We Think iCAD (NASDAQ:ICAD) Needs To Drive Business Growth Carefully
Jun 21Will iCAD (NASDAQ:ICAD) Spend Its Cash Wisely?
Feb 10Is iCAD (NASDAQ:ICAD) In A Good Position To Invest In Growth?
Nov 09Companies Like iCAD (NASDAQ:ICAD) Are In A Position To Invest In Growth
Jun 24iCAD (NASDAQ:ICAD) Is In A Good Position To Deliver On Growth Plans
Feb 23iCAD: Downside Seems Limited
Jan 16iCAD, Inc. (NASDAQ:ICAD) Analysts Just Cut Their EPS Forecasts Substantially
Jan 06Here's Why We're Not Too Worried About iCAD's (NASDAQ:ICAD) Cash Burn Situation
Nov 11Shareholder Returns
| ICAD | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | -1.6% | -3.2% | -2.6% |
| 1Y | 2.2% | -0.03% | 24.5% |
Return vs Industry: ICAD exceeded the US Healthcare Services industry which returned -2.5% over the past year.
Return vs Market: ICAD underperformed the US Market which returned 23.1% over the past year.
Price Volatility
| ICAD volatility | |
|---|---|
| ICAD Average Weekly Movement | 13.9% |
| Healthcare Services Industry Average Movement | 9.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ICAD's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ICAD's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 68 | Dana Brown | www.icadmed.com |
iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.
iCAD, Inc. Fundamentals Summary
| ICAD fundamental statistics | |
|---|---|
| Market cap | US$48.23m |
| Earnings (TTM) | -US$5.30m |
| Revenue (TTM) | US$18.94m |
2.5x
P/S Ratio-9.1x
P/E RatioIs ICAD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ICAD income statement (TTM) | |
|---|---|
| Revenue | US$18.94m |
| Cost of Revenue | US$2.37m |
| Gross Profit | US$16.57m |
| Other Expenses | US$21.88m |
| Earnings | -US$5.30m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.20 |
| Gross Margin | 87.51% |
| Net Profit Margin | -28.01% |
| Debt/Equity Ratio | 0% |
How did ICAD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 01:47 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
iCAD, Inc. is covered by 13 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrew D'Silva | B. Riley Securities, Inc. |
| Marie Thibault | BTIG |
| Michael Gorman | BTIG |